Composition: Maxpro® tablet 20mg: Each enteric coated tablet contains Esomeprazole 20mg as Esomeprazole Magnesium Trihydrate USP. Maxpro® tablet 40mg: Each enteric coated tablet contains Esomeprazole 40mg as Esomeprazole Magnesium Trihydrate USP. Maxpro® capsule 20mg: Each capsule contains Esomeprazole 20mg as Esomeprazole Magnesium Trihydrate USP in enteric coated pellets. Maxpro® capsule 40mg: Each capsule contains Esomeprazole 40mg as Esomeprazole Magnesium Trihydrate USP in enteric coated pellets. Pharmacological action: Esomeprazole, the S-isomer of Omeprazole, reduces gastric acid secretion through specific inhibition of the acid pump in the parietal cell, where it is concentrated and converted to the active form in the acid environment of the secretary canaliculi and inhibits the enzyme H+K+ATPase -the acid pump. Indications: The FDA approved Esomeprazole for maintenance of healing of erosive esophagitis and in combination with Amoxicillin and Clarithromycin, for the eradication of Helicobacter pylori infection in patients with duodenal ulcer disease. The FDA approved Esomeprazole for risk reduction of NSAID induced stomach ulcer. Maxpro® tablets/capsules are indicated for: Gastroesophageal Reflux Disease (GERD): ❉ treatment of erosive reflux esophagitis ❉ long-term management of patients with healed esophagitis to prevent relapse ❉ symptomatic treatment of gastroesophageal reflux disease (GERD) In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori: ❉ healing of Helicobacter pylori associates duodenal ulcer ❉ prevention of relapse of peptic ulcers in patient with Helicobacter pylori associated ulcer disease